Kentera (Oxybutynin) medicated plaster is the sixth option for symptomatic treatment of urge incontinence.
The plaster is applied every 3 to 4 days. The efficacy in terms of reduction in the frequency of incontinence episodes is comparable to other medical preparations for urge incontinence, but these are all formulated as tablets to be dosed one or more times a day.
The most important adverse effects are local reactions from the plaster, which occurs with approx. 23% and leads to cessation for almost 9% of patients. The anticholinergic adverse effects are probably less frequent than for other medical formulations for the treatment of urge incontinence. Kentera is primarily recommended for patients, who do not comply with oral formulations or who are subject to considerable anticholinergic adverse effects of other medicinal products. For other patients with urge incontinence, Kentera seems to lack advantages that counterbalance the skin reactions.
Kentera was marketed on June 20, 2005 and the cost of 24 plasters is DKK 1363.30. Thereby, Kentera is slightly cheaper than Detrusitol, but more expensive than the other medicinal products.
Last modified: December 7th 2005